|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-8-28
|
|
pubmed:abstractText |
To compare the estimated long-term outcomes, costs, and cost-effectiveness of tipranavir boosted with ritonavir (TPV/r) versus investigator-selected ritonavir-boosted comparator protease inhibitor (CPI/r) using the observed 48-week data from the RESIST trials in a previously published Markov model.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
225-37
|
|
pubmed:meshHeading |
pubmed-meshheading:18753117-Adolescent,
pubmed-meshheading:18753117-Adult,
pubmed-meshheading:18753117-Aged,
pubmed-meshheading:18753117-Aged, 80 and over,
pubmed-meshheading:18753117-Clinical Trials as Topic,
pubmed-meshheading:18753117-Cost-Benefit Analysis,
pubmed-meshheading:18753117-Drug Therapy, Combination,
pubmed-meshheading:18753117-Female,
pubmed-meshheading:18753117-HIV Infections,
pubmed-meshheading:18753117-HIV Protease Inhibitors,
pubmed-meshheading:18753117-Humans,
pubmed-meshheading:18753117-Male,
pubmed-meshheading:18753117-Markov Chains,
pubmed-meshheading:18753117-Middle Aged,
pubmed-meshheading:18753117-Pyridines,
pubmed-meshheading:18753117-Pyrones,
pubmed-meshheading:18753117-Quality-Adjusted Life Years,
pubmed-meshheading:18753117-Ritonavir,
pubmed-meshheading:18753117-United States
|
|
pubmed:articleTitle |
Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.
|
|
pubmed:affiliation |
Medical University of South Carolina, Charleston, South Carolina 29425, USA. simpsonk@musc.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
